Subcutaneous Immunoglobulins in the Treatment of Chronic Immune-mediated Neuropathies

Overview

Journal Ther Adv Neurol Disord

Specialty Neurology

Date 2016 Jul 2

PMID 27366241

Citations 7

Authors

Verena I Leussink

Hans-Peter Hartung

Bernd C Kieseier

Mark Stettner

Affiliations

Soon will be listed here.

Abstract

Intravenous immunoglobulins represent an established therapy for the treatment of chronic immune-mediated neuropathies, specifically chronic inflammatory demyelinating polyradiculoneuropathies (CIDPs) as well as multifocal motor neuropathies (MMNs). For the treatment of antibody deficiency syndromes, subcutaneous immunoglobulins (SCIgs) have represented a mainstay for decades. An emerging body of evidence suggests that SCIg might also exhibit clinical efficacy in CIDP and MMN. This article reviews the current evidence for clinical effectiveness, as well as safety of SCIg for the treatment of immune-mediated neuropathies, and addresses remaining open questions in this context. We conclude that despite the need for controlled long-term studies to demonstrate long-term efficacy of SCIg in immune-mediated neuropathies, SCIg may already represent a potential therapeutic alternative for selected patients.

Citing Articles

Cross-Reactivity of Antibodies in Intravenous Immunoglobulin Preparation for Protection against SARS-CoV-2.

Osaka T, Yamamoto Y, Soma T, Yanagisawa N, Nagata S Microorganisms. 2023; 11(2).

PMID: 36838436 PMC: 9959286. DOI: 10.3390/microorganisms11020471.

The influence of the COVID-19 pandemic on patients with chronic inflammatory demyelinating polyradiculoneuropathy.

Stojanov A, Bozovic I, Stojanov J, Palibrk A, Djordjevic G, Basta I Clin Neurol Neurosurg. 2021; 205:106654.

PMID: 33932773 PMC: 8055522. DOI: 10.1016/j.clineuro.2021.106654.

Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIg.

Beydoun S, Sharma K, Bassam B, Pulley M, Shije J, Kafal A Front Neurol. 2021; 12:638816.

PMID: 33763019 PMC: 7982536. DOI: 10.3389/fneur.2021.638816.

[Aspects of nutrition for prevention and treatment of chronic neurological diseases].

Leussink V Nervenarzt. 2019; 90(8):843-857.

PMID: 31375848 DOI: 10.1007/s00115-019-0756-9.

Immune Globulin Subcutaneous (Human) 20% (Hizentra): A Review in Chronic Inflammatory Demyelinating Polyneuropathy.

Lamb Y, Syed Y, Dhillon S CNS Drugs. 2019; 33(8):831-838.

PMID: 31347096 DOI: 10.1007/s40263-019-00655-x.

References

Berger M, McCallus D, Shin-Yi Lin C . Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies. J Peripher Nerv Syst. 2013; 18(4):275-96. PMC: 4285221. DOI: 10.1111/jns5.12048. View

Eftimov F, Vermeulen M, de Haan R, van den Berg L, van Schaik I . Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst. 2009; 14(2):93-100. DOI: 10.1111/j.1529-8027.2009.00218.x. View

Kieseier B, Dalakas M, Hartung H . Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology. 2002; 59(12 Suppl 6):S7-12. DOI: 10.1212/wnl.59.12_suppl_6.s7. View

Markvardsen L, Christiansen I, Andersen H, Jakobsen J . Headache and Nausea after Treatment with High-Dose Subcutaneous versus Intravenous Immunoglobulin. Basic Clin Pharmacol Toxicol. 2015; 117(6):409-12. DOI: 10.1111/bcpt.12428. View

Harbo T, Andersen H, Hess A, Hansen K, Sindrup S, Jakobsen J . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol. 2009; 16(5):631-8. DOI: 10.1111/j.1468-1331.2009.02568.x. View

Shin-Yi Lin C, Krishnan A, Park S, Kiernan M . Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol. 2011; 68(7):862-9. DOI: 10.1001/archneurol.2011.137. View

Koski C . Initial and long-term management of autoimmune neuropathies. CNS Drugs. 2005; 19(12):1033-48. DOI: 10.2165/00023210-200519120-00005. View

Misbah S, Baumann A, Fazio R, Dacci P, Schmidt D, Burton J . A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst. 2011; 16(2):92-7. DOI: 10.1111/j.1529-8027.2011.00330.x. View

Lehmann H, Hoffmann F, Fusshoeller A, Meyer Zu Horste G, Hetzel R, Hartung H . The clinical value of therapeutic plasma exchange in multifocal motor neuropathy. J Neurol Sci. 2008; 271(1-2):34-9. DOI: 10.1016/j.jns.2008.02.022. View

10.

Dacci P, Riva N, Scarlato M, Andresen I, Schmidt D, Comi G . Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report. Neurol Sci. 2010; 31(6):829-31. DOI: 10.1007/s10072-010-0352-z. View

11.

Gardulf A . Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007; 21(2):105-16. DOI: 10.2165/00063030-200721020-00005. View

12.

Markvardsen L, Harbo T, Sindrup S, Christiansen I, Andersen H, Jakobsen J . Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol. 2014; 21(12):1465-70. DOI: 10.1111/ene.12513. View

13.

Pestronk A, Cornblath D, Ilyas A, Baba H, Quarles R, Griffin J . A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988; 24(1):73-8. DOI: 10.1002/ana.410240113. View

14.

Yuki N . Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey. Proc Jpn Acad Ser B Phys Biol Sci. 2012; 88(7):299-326. PMC: 3422685. DOI: 10.2183/pjab.88.299. View

15.

Lazzaro C, Lopiano L, Cocito D . Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis. Neurol Sci. 2014; 35(7):1023-34. DOI: 10.1007/s10072-014-1632-9. View

16.

Cocito D, Paolasso I, Peci E, Spagone E, Lopiano L . Improvement of quality of life in patients with chronic inflammatory demyelinating polyneuropathy shifting from 16 to 20% subcutaneous immunoglobulins. Neurol Sci. 2013; 34(11):2061-2. DOI: 10.1007/s10072-013-1426-5. View

17.

Devaux J . Antibodies to gliomedin cause peripheral demyelinating neuropathy and the dismantling of the nodes of Ranvier. Am J Pathol. 2012; 181(4):1402-13. PMC: 5691341. DOI: 10.1016/j.ajpath.2012.06.034. View

18.

Yuki N, Hartung H . Guillain-Barré syndrome. N Engl J Med. 2012; 366(24):2294-304. DOI: 10.1056/NEJMra1114525. View

19.

Bonilla F . Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol. 2008; 122(6):1238-9. DOI: 10.1016/j.jaci.2008.08.033. View

20.

BRUTON O . Agammaglobulinemia. Pediatrics. 1952; 9(6):722-8. View